Niraparib Maintains Quality of Life

September 13, 2017 8:40 pm

Administering niraparib to patients with recurrent ovarian cancer after a complete response (CR) or partial response (PR) to platinum-based chemotherapy may allow patients to continuously maintain their quality of life (QOL) during treatment, according to a study presented at the … Read more

Niraparib Approved for Ovarian Cancer Maintenance Tx

March 27, 2017 4:33 am

Niraparib (Zejula, Tesaro) has been approved by the US Food and Drug Administration (FDA) for use in the maintenance treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are in complete or partial … Read more

TESARO’s Niraparib Significantly Improved Progression-Free Survival

June 29, 2016 7:03 pm

TESARO, Inc. (NASDAQ:TSRO), an oncology-focused biopharmaceutical company, today announced that the Phase 3 NOVA trial of niraparib successfully achieved its primary endpoint of progression-free survival (PFS). This trial demonstrated that niraparib significantly prolonged PFS compared to control among patients who … Read more